Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Comparative Genomic Analyses Defines Shared and Unique Features of cHL and PMBL and New Mechanisms of Sensitivity to PD-1 Blockade

Blood (2019) 134 (Supplement_1): 1493.

https://doi.org/10.1182/blood-2019-131904

Published: 2019

Journal Articles

Validation of the Genetically-Defined DLBCL Subtypes and Generation of a Parsimonious Probabilistic Classifier

Bjoern Chapuy, MD PhD, Chip Stewart, PhD, Timothy Wood, Andrew Dunford, MS, Kirsty Wienand, PhD, Gad Getz, PhD, Margaret A. Shipp, MD

Blood (2019) 134 (Supplement_1): 920.

https://doi.org/10.1182/blood-2019-131250

Published: 2019

Journal Articles

Novel Epigenetic Vulnerabilities for Diffuse Large B-Cell Lymphoma

Deepak Jha, PhD, George Q. Daley, MD PhD, Benoit Laurent, PhD, Cheng Zhang, PhD, Caroline Kubaczka, PhD, Bjoern Chapuy, MD PhD, Patricia Sousa, Pavlos Missios, MD PhD, R. Grant Rowe, MD PhD, Yu-Chung Huang, MD, Yang Tan, Jessica Barragan, Trista North, PhD, Thorsten Schlaeger, PhD, Hu Li, PhD, Yang Shi, PhD, Margaret A. Shipp, MD

Blood (2018) 132 (Supplement 1): 2600.

https://doi.org/10.1182/blood-2018-99-115030

Published: 2018

Journal Articles

Genetically-Defined Diffuse Large B-Cell Lymphoma Subsets Arise By Distinct Pathogenetic Mechanisms and Predict Outcome

Bjoern Chapuy, MD PhD, Chip Stewart, PhD, Andrew Dunford, MS, Jaegil Kim, PhD, Atanas Kamburow, PhD, Robert A. Redd, MS, Michael Lawrence, PhD, Margaretha G.M. Roemer, MSc, Amy Li, Marita Ziepert, PhD, Annette M. Staiger, PhD, Jeremiah Wala, Matthew D. Ducar, MS, Ignaty Leshchiner, PhD, Esther Rheinbay, PhD, Amaro Taylor-Weiner, BS, Caroline Coughlin, BS, Julian Hess, Chandra Pedamallu, Dimitri Livitz, Daniel Rosebrock, Mara Rosenberg, Adam Tracy, Heike Horn, Paul van Hummelen, Andrew L Feldman, MD, Brian K Link, MD, Anne J Novak, PhD, James R. Cerhan, MD PhD, Thomas M Habermann, MD, Reiner Siebert, PhD, Andreas Rosenwald, Aaron R. Thorner, PhD, Matthew Meyerson, MDPhD, Todd R. Golub, MD, Rameen Beroukhim, Gerald Wulf, MD, German Ott, MD, Scott J. Rodig, MDPhD, Stefano Monti, PhD, Donna S. Neuberg, ScD, Markus Loeffler, MD, Michael Pfreundschuh, MD, Lorenz Trümper, MD, Gad Getz, PhD, Margaret A. Shipp, MD

Blood (2017) 130 (Supplement 1): 38.

https://doi.org/10.1182/blood.V130.Suppl_1.38.38

Published: 2017

Journal Articles

In Silico and Functional Characterization of TBL1XR1 as a Tumor Suppressor in Large B-Cell Lymphomas

Bjoern Chapuy, MD PhD, Atanas Kamburov, PhD, Caroline A Coughlin, Chip Stewart, PhD, Andrew Dunford, Miyuki Aono, Jens Loeber, Christopher Sauer, Arthur Su, Margaretha G M Roemer, Scott J Rodig, Gad Getz, PhD, Margaret A. Shipp, MD

Blood (2016) 128 (22): 612.

https://doi.org/10.1182/blood.V128.22.612.612

Published: 2016

Journal Articles

Nivolumab (Anti-PD1) Therapy for Relapsed/ Refractory Primary Central Nervous System Lymphoma and Primary Testicular Lymphoma

Lakshmi Nayak, MD, Fabio Iwamoto, MD, Ann S. LaCasce, MD, Srinivasan Mukundan, Jr., Margaretha G M Roemer, Bjoern Chapuy, MD PhD, Philippe Armand, MD PhD, Scott J. Rodig, Margaret A. Shipp, MD

Blood (2016) 128 (22): 930.

https://doi.org/10.1182/blood.V128.22.930.930

Published: 2016

Journal Articles

SFRP4-Mediated Inhibition of Canonical Wnt-Signaling in DLBCL

Raphael Koch, MD, Bjoern Chapuy, MD PhD

Blood (2015) 126 (23): 3999.

https://doi.org/10.1182/blood.V126.23.3999.3999

Published: 2015

Journal Articles

PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome

Margaretha GM Roemer, MS, Ranjana H Advani, MD, Azra H. Ligon, PhD, Yasodha Natkunam, MD PhD, Robert A Redd, MS, Heather Homer, Courtney Connelly, Heather H. Sun, Sarah E. Daadi, Bjoern Chapuy, MD PhD, Daphne de Jong, MD PhD, Richard T. Hoppe, MD, Donna S Neuberg, ScD, Scott J Rodig, MD PhD, Margaret A. Shipp, MD

Blood (2015) 126 (23): 176.

https://doi.org/10.1182/blood.V126.23.176.176

Published: 2015

Journal Articles

Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma - Preliminary Safety, Efficacy and Biomarker Results of a Phase I Study

Philippe Armand, MD PhD, Stephen M. Ansell, MD PhD, Alexander M. Lesokhin, MD, Ahmad Halwani, MD, Michael M. Millenson, MD, Stephen J. Schuster, MD, John Timmerman, MD, Ivan Borrello, MD, Martin Gutierrez, MD, Emma C. Scott, MD, Deepika Cattry, MSc, CCRP, Bjoern Chapuy, MD PhD, Azra H. Ligon, PhD, Scott J. Rodig, MD PhD, Lili Zhu, MSc, Joseph F. Grosso, PhD, Su Young Kim, MD PhD, Margaret A. Shipp, MD

Blood (2014) 124 (21): 289.

https://doi.org/10.1182/blood.V124.21.289.289

Published: 2014

Journal Articles

Preliminary Results of a Phase I Study of Nivolumab (BMS-936558) in Patients with Relapsed or Refractory Lymphoid Malignancies

Blood (2014) 124 (21): 291.

https://doi.org/10.1182/blood.V124.21.291.291

Published: 2014

Journal Articles

GNB1 Activating Mutations Promote Myeloid and Lymphoid Neoplasms Targetable By Combined PI3K/mTOR Inhibition

Blood (2014) 124 (21): 3567.

https://doi.org/10.1182/blood.V124.21.3567.3567

Published: 2014

Journal Articles

The BRAF Pseudogene Is a Proto-Oncogenic Competitive Endogenous RNA

Florian Karreth, PhD, Markus Reschke, PhD, Bjoern Chapuy, MD PhD, Margaret A. Shipp, MD, Roberto Chiarle, MD, Pier Paolo Pandolfi, MD PhD

Blood (2014) 124 (21): 263.

https://doi.org/10.1182/blood.V124.21.263.263

Published: 2014

Journal Articles

Actionable Genetic Features of Primary Testicular and Primary Central Nervous System Lymphomas

Blood (2014) 124 (21): 74.

https://doi.org/10.1182/blood.V124.21.74.74

Published: 2014

Journal Articles

Type II JAK2 Inhibitor NVP-CHZ868 Is Active in Vivo Against JAK2-Dependent B-Cell Acute Lymphoblastic Leukemias (B-ALLs)

Blood (2014) 124 (21): 3713.

https://doi.org/10.1182/blood.V124.21.3713.3713

Published: 2014

Journal Articles

Preclinical Analyses Of The Chemical JAK2 Inhibitor, SAR302503, In Classical Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma

Yansheng Hao, MD, PhD, Bjoern Chapuy, MD, PhD, Stefano Monti, PhD, Heather Sun, Scott J. Rodig, MD, PhD, Margaret A Shipp, MD

Blood (2013) 122 (21): 4230.

https://doi.org/10.1182/blood.V122.21.4230.4230

Published: 2013

Journal Articles

The Beta-Subunit Of Heterotrimeric G Proteins Harbors Gain-Of-Function Mutations In Multiple Hematologic Malignancies

Akinori Yoda, PhD, Guillaume Adelmant, PhD, Nobuaki Shindoh, PhD, Bjoern Chapuy, MD, PhD, Yuka Yoda, MPh, Oliver Weigert, Nadja Kopp, Shuo-Chieh Wu, Sunhee S. Kim, Huiyun Liu, Trevor Tivey, Jeffrey W. Tyner, Jason Gotlib, MD, MS, Michael W. Deininger, MD, PhD, Shannon Turley, PhD, Jarrod A Marto, PhD, Andrew A. Lane, MD, PhD, David M. Weinstock, MD

Blood (2013) 122 (21): 2510.

https://doi.org/10.1182/blood.V122.21.2510.2510

Published: 2013

Journal Articles

Disruption Of Super Enhancer-Driven Cancer Dependencies In Diffuse Large B-Cell Lymphoma

Bjoern Chapuy, MD, PhD, McKeown Michael, Charles Y. Lin, PhD, Stefano Monti, PhD, Margaretha GM Roemer, Jun Qi, Peter B. Rahl, PhD, Heather Sun, Kelly T. Yeda, Andrew L. Kung, MD, PhD, Scott J. Rodig, MD, PhD, Richard A. Young, PhD, Margaret A. Shipp, MD, James E. Bradner, MD

Blood (2013) 122 (21): 3021.

https://doi.org/10.1182/blood.V122.21.3021.3021

Published: 2013

Journal Articles

Exosome Mediated Wnt-Signaling Augments Side Population In Aggressive Lymphoma

Raphael Koch, Martin Demant, Thiha Aung, Annemarie Guentsch, Nina Diering, Bjoern Chapuy, MD, PhD, Lorenz Truemper, Gerald Wulf, MD

Blood (2013) 122 (21): 3010.

https://doi.org/10.1182/blood.V122.21.3010.3010

Published: 2013

Journal Articles

CXCR4 Upregulation Is a Biomarker Of Sensitivity To Targeted Inhibition Of B-Cell Receptor Signaling In Diffuse Large B-Cell Lymphoma

Linfeng Chen, PhD, Yansheng Hao, MD, PhD, Jing Ouyang, PhD, Bjoern Chapuy, MD, PhD, Donna S. Neuberg, ScD, Thomas M Habermann, MD, Przemyslaw Juszczynski, MD, PhD, Scott J Rodig, MD, PhD, Stefano Monti, PhD, Margaret A Shipp, MD

Blood (2013) 122 (21): 631.

https://doi.org/10.1182/blood.V122.21.631.631

Published: 2013

Journal Articles

A Structural Basis for p53-Deficiency, Deregulated Cell Cycle and Unfavorable Outcome in Diffuse Large B-Cell Lymphoma

Bjoern Chapuy, MD, PhD, Stefano Monti, PhD, Kunihiko Takeyama, MD, PhD, Scott J Rodig, MD, PhD, Yansheng Hao, MD, PhD, Kelly T Yeda, Haig Inguilizian, MD, Craig Mermel, Treeve Currie, Ahmet Dogan, MD, PhD, Jeffery Kutok, MD, PhD, Rameen Beroukhim, MD, PhD, Donna S. Neuberg, ScD, Thomas M Habermann, MD, Gad Getz, PhD, Andrew L. Kung, MD, PhD, Todd R. Golub, MD, Margaret A. Shipp, MD

Blood (2012) 120 (21): 1534.

https://doi.org/10.1182/blood.V120.21.1534.1534

Published: 2012

NARROW

Comparative Genomic Analyses Defines Shared and Unique Features of cHL and PMBL and New Mechanisms of Sensitivity to PD-1 Blockade

Validation of the Genetically-Defined DLBCL Subtypes and Generation of a Parsimonious Probabilistic Classifier

Novel Epigenetic Vulnerabilities for Diffuse Large B-Cell Lymphoma

Genetically-Defined Diffuse Large B-Cell Lymphoma Subsets Arise By Distinct Pathogenetic Mechanisms and Predict Outcome

In Silico and Functional Characterization of TBL1XR1 as a Tumor Suppressor in Large B-Cell Lymphomas

Nivolumab (Anti-PD1) Therapy for Relapsed/ Refractory Primary Central Nervous System Lymphoma and Primary Testicular Lymphoma

SFRP4-Mediated Inhibition of Canonical Wnt-Signaling in DLBCL

PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome

Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma - Preliminary Safety, Efficacy and Biomarker Results of a Phase I Study

Preliminary Results of a Phase I Study of Nivolumab (BMS-936558) in Patients with Relapsed or Refractory Lymphoid Malignancies

GNB1 Activating Mutations Promote Myeloid and Lymphoid Neoplasms Targetable By Combined PI3K/mTOR Inhibition

The BRAF Pseudogene Is a Proto-Oncogenic Competitive Endogenous RNA

Actionable Genetic Features of Primary Testicular and Primary Central Nervous System Lymphomas

Type II JAK2 Inhibitor NVP-CHZ868 Is Active in Vivo Against JAK2-Dependent B-Cell Acute Lymphoblastic Leukemias (B-ALLs)

Preclinical Analyses Of The Chemical JAK2 Inhibitor, SAR302503, In Classical Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma

The Beta-Subunit Of Heterotrimeric G Proteins Harbors Gain-Of-Function Mutations In Multiple Hematologic Malignancies

Disruption Of Super Enhancer-Driven Cancer Dependencies In Diffuse Large B-Cell Lymphoma

Exosome Mediated Wnt-Signaling Augments Side Population In Aggressive Lymphoma

CXCR4 Upregulation Is a Biomarker Of Sensitivity To Targeted Inhibition Of B-Cell Receptor Signaling In Diffuse Large B-Cell Lymphoma

A Structural Basis for p53-Deficiency, Deregulated Cell Cycle and Unfavorable Outcome in Diffuse Large B-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only